HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Botox approval

This article was originally published in The Rose Sheet

Executive Summary

Allergan will market prescription drug Botox Cosmetic with $40 mil.-$50 mil. ad campaign following FDA approval April 15, Irvine, Calif. company says. Botulinum Toxin Type A, already widely used in cosmetic surgery, was formally approved by the agency for cosmetic use to "to temporarily improve the appearance of moderate to severe frown lines between the eyebrows," FDA announces. When injected into skin in small doses, the toxin paralyzes or weakens the muscle, FDA says, noting the majority of investigators and 405 patients evaluated in placebo-controlled, multi-center randomized clinical trials noticed an improvement in lines when injected with Botox. More than 850,000 people had Botox injections in 2001, according to American Society of Plastic Surgeons...

You may also be interested in...



Botox Cosmetic ads cited by FDA

Allergan's Botox Cosmetic (botulinum toxin A) "WOW" TV reminder ad discloses anti-wrinkle agent's indication by discussing age, focusing on complexion and image and directing consumer to a dermatologist or plastic surgeon, FDA says in a Sept. 5 letter to firm, requesting ads be discontinued. Under FDA rules, reminder ads need not include a full summary of side effects as long as the product's use is not disclosed. However, Allergan's ad "strongly suggest[s] that the product is intended to treat the signs of aging or glabellar lines," FDA says and should therefore be revised and submitted to the agency for review prior to airing. In a statement Sept. 12, Allergan said it plans to respond to FDA's concerns by Sept. 16. Botox was approved in April (1"The Rose Sheet" April 22, 2002, In Brief)...

E.l.f. Puts Premium On ‘Clean Beauty’ With First Strategic Acquisition: W3ll People

W3ll People is expected to add a relatively modest $7m to e.l.f. Beauty’s fiscal 2021 top line, but the brand has “major white space” opportunities, including at Target, e.l.f.’s longest-standing customer. Further, its plant-based product line includes 40 “EWG Verified” products, reflecting expertise e.l.f. is eager to tap.

UCB Pins Growth Hopes On Burgeoning Late-Stage Pipeline

UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.

 

UsernamePublicRestriction

Register

RS010214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel